1 |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-63.
|
2 |
Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 221-31.
|
3 |
SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023 [J]. CA: a cancer journal for clinicians, 2023, 73(1): 17-48.
|
4 |
Alduais Y, Zhang HJ, Fan F, et al. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment[J]. Medicine, 2023, 102(8): e32899.
|
5 |
Buriolla S, Pelizzari G, Corvaja C, et al. Immunotherapy in NSCLC patients with brain metastases[J]. Int J Mol Sci, 2022, 23(13): 7068.
|
6 |
Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline[J]. J Clin Oncol, 2022, 40(5): 492-516.
|
7 |
Reck M, Ciuleanu TE, Lee JS, et al. Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 part 1[J]. J Thorac Oncol, 2023, 18(8): 1055-69.
|
8 |
Mavrikios A, Remon J, Quevrin C, et al. Local control strategies for management of NSCLC with oligoprogressive disease[J]. Cancer Treat Rev, 2023, 120: 102621.
|
9 |
王 芳, 杨兴嫕, 孙 琮, 等. 气血瘀滞型非小细胞肺癌患者 “瘀毒” 病机临床特征及补肺化瘀汤辅助治疗干预机制[J]. 广州中医药大学学报, 2024, 41(1): 68-77.
|
10 |
刘志斌, 张 磊. 张维骏教授基于 “痰瘀互结” 理论治疗非小细胞肺癌临床经验[J]. 广西中医药, 2022, 45(5): 47-9.
|
11 |
陈颖娟, 陈 晓, 李海峰, 等. 泽漆汤症证病机方药探析[J]. 上海中医药杂志, 2023, 57(1): 66-70.
|
12 |
周 兰, 高红芳. 从正虚络阻探讨泽漆汤辨治肺癌[J]. 河南中医, 2023, 43(4): 492-5.
|
13 |
王 冬, 张翔宇, 邵莹莹, 等. 中药泽漆及其复方制剂抗肿瘤药理作用与临床应用研究进展[J]. 天津中医药, 2023, 40(3): 402-8.
|
14 |
霍 雁, 李淑芳. 黄吉赓辨治痰饮咳喘经验[J]. 中医文献杂志, 2021, 39(5): 69-71.
|
15 |
王 嘉. 泽漆汤治疗肺癌恶性胸腔积液及对T淋巴细胞亚群影响的临床观察[D]. 济南: 山东中医药大学, 2021.
|
16 |
高春迪. 基于PI3K/AKT信号通路探讨泽漆汤对肺腺癌的干预机制[D]. 济南: 山东中医药大学, 2022.
|
17 |
王 今, 沈 佳. 沈佳运用《金匮要略》泽漆汤加减治疗肺结节经验[J]. 中医药导报, 2021, 27(10): 187-90.
|
18 |
Li XQ, Bai YL, Zhang DL, et al. Euphornin reduces proliferation of human cervical adenocarcinoma HeLa cells through induction of apoptosis and G2/M cell cycle arrest[J]. Onco Targets Ther, 2018, 11: 4395-405.
|
19 |
Mu HY, Gong CY, Zhang RJ, et al. Diterpenoids from Euphorbia helioscopia and their enhancement of NK cell-mediated killing of NSCLC cells[J]. Bioorg Chem, 2022, 119: 105534.
|
20 |
阳 柳, 范先基, 宁雪坚, 等. 葶苈泽漆汤对肺癌恶性胸腔积液患者生存期及Th1、Th2细胞因子失衡的影响[J]. 解放军预防医学杂志, 2019, 37(7): 150-1.
|
21 |
孙 宇, 刘 琳, 王英力. 泽漆扶正散结汤联合化疗治疗乳腺癌疗效观察[J]. 现代中西医结合杂志, 2022, 31(6): 775-9.
|
22 |
Cheng JS, Han W, Wang ZY, et al. Hepatocellular carcinoma growth is inhibited by Euphorbia helioscopia L. extract in nude mice xenografts[J]. Biomed Res Int, 2015: 601015.
|
23 |
邵 远, 柳鹏程, 程军胜, 等. 泽漆乙酸乙酯提取物对SGC7901/DDP多药耐药性的逆转及机制[J]. 中成药, 2017, 39(8): 1713-7.
|
24 |
Yan ZK, Lai ZJ, Lin JM. Anticancer properties of traditional Chinese medicine[J]. Comb Chem High Throughput Screen, 2017, 20(5): 423-9.
|
25 |
曹 策, 李玲美, 訾明杰, 等. 医学研究中动物实验样本量的确定方法[J]. 中国比较医学杂志, 2023, 33(2): 99-105.
|
26 |
李 雪, 姜懿洋, 李彬彬, 等. 泽漆汤治疗肺癌的研究进展 [J/OL]. 中华中医药学刊,2024,
|
27 |
Cui JH, Zhang C, Lee JE, et al. MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state[J]. Nat Cell Biol, 2023, 25(1): 145-58.
|
28 |
Sahu SK, Agirre E, Inayatullah M, et al. A complex epigenome-splicing crosstalk governs epithelial-to-mesenchymal transition in metastasis and brain development[J]. Nat Cell Biol, 2022, 24(8): 1265-77.
|
29 |
胥孜杭, 朱杨壮壮, 张 飞, 等. 泽漆汤对肺癌原位模型小鼠的抑制作用[J]. 中国实验方剂学杂志, 2019, 25(14): 6-12.
|
30 |
张永为, 夏华峰, 范丽萍, 等. 泽漆汤对小鼠Lewis肺癌抑制作用及survivin蛋白表达的影响[J]. 中华中医药学刊, 2012, 30(11): 2489-91, 后插8.
|
31 |
杨唯曦. 泽漆扶正散结汤联合化疗方案治疗乳腺癌患者的临床效果[J]. 中国实用医药, 2023, 18(15): 141-3.
|
32 |
唐 琳, 顾佳麟, 杨汪银, 等. 经方治疗肿瘤相关咳嗽的应用及研究进展[J]. 中医药临床杂志, 2020, 32(7): 1399-401.
|